King Pharmaceuticals Inc.: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for King in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark King's performance against key rivals in the prescription pharmaceutical sector

*Assess the impact of the acquisition of Alpharma on King's forecast performance

*Analyze how the invalidation of King's Altace and Skelaxin patents will affect the company's revenue performance over 200814


Report Highlights

[Studien Infos ausblenden]

ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
King Pharmaceuticals: PharmaVitae forecasts at a glance 8
Strategic insight 9
Challenging times as key products face generic competition 9
Alpharma acquisition has significantly improved King's outlook 10
King-Alpharma combination creates a key player in the pain market 12
SWOT analysis 14
Strengths 14
Weaknesses 15
Opportunities 15
Threats 16
Table of Contents 17
Table of figures 19
Chapter 3 Quarterly news update 20
Quarterly sales update, Q2 2009 20
Product developments 20
Deals and alliances 21
Product deals 21
M&A activity 21
Company announcements 22
Future product milestones 22
Chapter 4 Company introduction 23
Key findings 23
Background 24
Key corporate developments 24
M&A history 25
Early M&A following success of Altace 25
Elan deal creates life after Altace 25
Mylan acquisition failed to materialize 25
Alpharma acquisition completed in December 2008 26
Current corporate structure 27
Pharmaceuticals business unit structure 28
Chapter 5 Company sales 29
Key findings 29
Prescription pharmaceutical sales and growth rate analysis, 2002-14 30
Product analysis 32
Product analysis, 2002-08 33
Growth drivers 34
Growth resistors 35
Product analysis, 2008-14 36
Growth drivers 37
Growth resistors 38
Therapy area analysis 39
Geographic analysis 42
Launch/core/expiry analysis 44
Explanation of launch/core/expiry analysis 44
Launch analysis, 2008-14 45
Core analysis, 2008-14 47
Expiry analysis, 2008-14 48
Launch/core/expiry configuration, 2008-14 50
Molecule type analysis 51
Externalization analysis 53
Chapter 6 Company financials 55
Key findings 55
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 56
Operating costs and profit analysis 58
Operating costs and profit analysis, 2002-08 59
Operating cost ratio and profit margin analysis, 2002-08 61
Operating cost ratio and profit margin analysis, 2008-14 62
Operating costs and profit analysis, 2008-14 64
Chapter 7 Key products and competitors 66
Key findings 66
Overview 67
Central nervous system 68
Remoxy 68
Overview 68
Sales forecast 69
Pipeline drug Remoxy set to launch in 2011 following approval delays 69
Remoxy's anti-abuse properties target an area of high unmet need 69
Flector 71
Overview 71
Sales forecast 72
Alpharma launches Flector in US in January 2008 72
Acurox 73
Overview 73
Sales forecast 74
Acurox proves another promising pain management candidate 74
Acurox also to target abuse-resistant market 75
Embeda 76
Overview 76
Sales forecast 77
Embeda gained via Alpharma acquisition 77
Abuse-resistant oxycodone expected to achieve greater market success 77
Avinza 78
Overview 78
Sales forecast 79
Once-daily pain treatment Avinza was acquired in 2007 79
Embeda to cannibalize revenues 79
Generic threat from Actavis puts long-term sales performance in jeopardy 79
Following Alpharma acquisition, King chooses Avinza and divests Kadian 80
Immunology and inflammation 81
EpiPen 81
Overview 81
Sales forecast 82
EpiPen sourced through Meridian acquisition in 2003 82
King acquires rights to market EpiPen directly in Canada 82
Competition from Sciele's TwinJect 83
Hematology 84
Thrombin-JMI 84
Overview 84
Sales forecast 85
Jones-derived Thrombin is King's second largest growth driver over 2002-08 85
New additions to Thrombin-JMI franchise intended to improve competitive edge 86
Cardiovascular 87
Altace 87
Overview 87
Sales forecast 88
Altace is King's biggest success story 88
Altace patent invalidation is major blow to King 88
Attempts to sustain the Altace brand are largely unsuccessful 89
Chapter 8 Appendix 90
R&D pipeline 90
References 91
Abbreviations 91
Exchange rates 92
About Datamonitor 93
About Datamonitor Healthcare 93
Datamonitor consulting 93
Disclaimer 95
List of Tables
Table 1: King - PharmaVitae forecasts at a glance 8
Table 2: King key product developments, 2009 20
Table 3: King product deals and alliances, 2009 21
Table 4: King M&A activity, 2009 21
Table 5: King company announcements, 2009 22
Table 6: King future product milestones, 2009-11 22
Table 7: King product portfolio overview ($m), 2002-08 33
Table 8: King product portfolio overview ($m), 2008-14 36
Table 9: King prescription pharmaceutical sales by therapy area ($m), 2008-14 40
Table 10: King prescription pharmaceutical sales by geographic region ($m), 2008-14 43
Table 11: King launch portfolio overview ($m), 2008-14 45
Table 12: King core portfolio overview ($m), 2008-14 47
Table 13: King expiry portfolio overview ($m), 2008-14 48
Table 14: King prescription pharmaceutical sales by molecule type ($m), 2008-14 52
Table 15: King prescription pharmaceutical sales by source ($m), 2008-14 54
Table 16: Total King sales by business unit ($m), 2002-08 56
Table 17: King operating revenue/cost analysis ($m), 2002-08 59
Table 18: King operating cost ratio analysis (% of total revenues), 2002-08 61
Table 19: King operating cost ratio analysis (% of total revenues), 2008-14 62
Table 20: King operating revenue/cost analysis ($m), 2008-14 64
Table 21: Key products overview 67
Table 22: Remoxy: overview 68
Table 23: Remoxy: sales forecast ($m), 2008-14 69
Table 24: Flector: overview 71
Table 25: Flector: sales forecast ($m), 2008-14 72
Table 26: Acurox: overview 73
Table 27: Acurox: sales forecast ($m), 2008-14 74
Table 28: Embeda: overview 76
Table 29: Embeda: sales forecast ($m), 2008-14 77
Table 30: Avinza: overview 78
Table 31: Avinza: sales forecast ($m), 2008-14 79
Table 32: EpiPen: overview 81
Table 33: EpiPen: sales forecast ($m), 2008-14 82
Table 34: Thrombin-JMI: overview 84
Table 35: Thrombin-JMI: sales forecast ($m), 2008-14 85
Table 36: Altace: overview 87
Table 37: Altace: sales forecast ($m), 2008-14 88
Table 38: King's R&D pipeline (Phase I-registration) 90
Table 39: Exchange rates, 2009 92
List of Figures
Figure 1: The PharmaVitae Explorer 3
Figure 2: King prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: King's financial performance ($m), 2002-14 7
Figure 4: King major growth drivers/resistors, 2002-14 9
Figure 5: King prescription pharmaceutical revenue by source company, 2002-14 11
Figure 6: King launch, core and expiry configuration, 2008-14 12
Figure 7: US analgesics market by company, percentage share (%), 2008-14 13
Figure 8: King SWOT analysis 14
Figure 9: Current corporate structure 27
Figure 10: Pharmaceuticals business unit structure 28
Figure 11: King prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 30
Figure 12: Key product sales ($m), 2002-14 32
Figure 13: King key sales growth drivers and resistors ($m), 2002-08 34
Figure 14: King key sales growth drivers and resistors ($m), 2008-14 37
Figure 15: King prescription pharmaceutical sales by therapy area ($m), 2002-14 39
Figure 16: King prescription pharmaceutical sales by geographic region ($m), 2002-14 42
Figure 17: King launch/core/expiry configuration ($m), 2008-14 50
Figure 18: King prescription pharmaceutical sales by molecule type ($m), 2002-14 51
Figure 19: King prescription pharmaceutical sales by source ($m), 2002-14 53
Figure 20: King operating revenue/cost analysis ($m), 2002-14 58

[Inhaltsverzeichnis ausblenden]

List of Tables
Table 1: King - PharmaVitae forecasts at a glance 8
Table 2: King key product developments, 2009 20
Table 3: King product deals and alliances, 2009 21
Table 4: King M&A activity, 2009 21
Table 5: King company announcements, 2009 22
Table 6: King future product milestones, 2009-11 22
Table 7: King product portfolio overview ($m), 2002-08 33
Table 8: King product portfolio overview ($m), 2008-14 36
Table 9: King prescription pharmaceutical sales by therapy area ($m), 2008-14 40
Table 10: King prescription pharmaceutical sales by geographic region ($m), 2008-14 43
Table 11: King launch portfolio overview ($m), 2008-14 45
Table 12: King core portfolio overview ($m), 2008-14 47
Table 13: King expiry portfolio overview ($m), 2008-14 48
Table 14: King prescription pharmaceutical sales by molecule type ($m), 2008-14 52
Table 15: King prescription pharmaceutical sales by source ($m), 2008-14 54
Table 16: Total King sales by business unit ($m), 2002-08 56
Table 17: King operating revenue/cost analysis ($m), 2002-08 59
Table 18: King operating cost ratio analysis (% of total revenues), 2002-08 61
Table 19: King operating cost ratio analysis (% of total revenues), 2008-14 62
Table 20: King operating revenue/cost analysis ($m), 2008-14 64
Table 21: Key products overview 67
Table 22: Remoxy: overview 68
Table 23: Remoxy: sales forecast ($m), 2008-14 69
Table 24: Flector: overview 71
Table 25: Flector: sales forecast ($m), 2008-14 72
Table 26: Acurox: overview 73
Table 27: Acurox: sales forecast ($m), 2008-14 74
Table 28: Embeda: overview 76
Table 29: Embeda: sales forecast ($m), 2008-14 77
Table 30: Avinza: overview 78
Table 31: Avinza: sales forecast ($m), 2008-14 79
Table 32: EpiPen: overview 81
Table 33: EpiPen: sales forecast ($m), 2008-14 82
Table 34: Thrombin-JMI: overview 84
Table 35: Thrombin-JMI: sales forecast ($m), 2008-14 85
Table 36: Altace: overview 87
Table 37: Altace: sales forecast ($m), 2008-14 88
Table 38: King's R&D pipeline (Phase I-registration) 90
Table 39: Exchange rates, 2009 92

List of Figures
Figure 1: The PharmaVitae Explorer 3
Figure 2: King prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: King's financial performance ($m), 2002-14 7
Figure 4: King major growth drivers/resistors, 2002-14 9
Figure 5: King prescription pharmaceutical revenue by source company, 2002-14 11
Figure 6: King launch, core and expiry configuration, 2008-14 12
Figure 7: US analgesics market by company, percentage share (%), 2008-14 13
Figure 8: King SWOT analysis 14
Figure 9: Current corporate structure 27
Figure 10: Pharmaceuticals business unit structure 28
Figure 11: King prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 30
Figure 12: Key product sales ($m), 2002-14 32
Figure 13: King key sales growth drivers and resistors ($m), 2002-08 34
Figure 14: King key sales growth drivers and resistors ($m), 2008-14 37
Figure 15: King prescription pharmaceutical sales by therapy area ($m), 2002-14 39
Figure 16: King prescription pharmaceutical sales by geographic region ($m), 2002-14 42
Figure 17: King launch/core/expiry configuration ($m), 2008-14 50
Figure 18: King prescription pharmaceutical sales by molecule type ($m), 2002-14 51
Figure 19: King prescription pharmaceutical sales by source ($m), 2002-14 53
Figure 20: King operating revenue/cost analysis ($m), 2002-14 58
[Tabellenverzeichnis ausblenden]